[PDF][PDF] Atherothrombosis: role of tissue factor link between diabetes, obesity and inflammation

P Meerarani, PR Moreno, G Cimmino, JJ Badimon - 2007 - academia.edu
P Meerarani, PR Moreno, G Cimmino, JJ Badimon
2007academia.edu
Atherothrombotic vascular disease is a complex disorder in which inflammation and
coagulation play a pivotal role. Rupture of high-risk, vulnerable plaques with the subsequent
tissue factor (TF) exposure is responsible for coronary thrombosis, the main cause of
unstable angina, acute myocardial infarction, and sudden cardiac death. Tissue factor (TF),
the key initiator of coagulation is an important modulator of inflammation. TF is widely
expressed in atherosclerotic plaques and found in macrophages, smooth muscle cells …
Atherothrombotic vascular disease is a complex disorder in which inflammation and coagulation play a pivotal role. Rupture of high-risk, vulnerable plaques with the subsequent tissue factor (TF) exposure is responsible for coronary thrombosis, the main cause of unstable angina, acute myocardial infarction, and sudden cardiac death. Tissue factor (TF), the key initiator of coagulation is an important modulator of inflammation. TF is widely expressed in atherosclerotic plaques and found in macrophages, smooth muscle cells, extracellular matrix and acellular lipid-rich core. TF expression can be induced by various stimulants such as C-reactive protein, oxLDL, hyperglycemia and adipocytokines. The bloodborn TF encrypted on the circulating microparticles derived from vascular cells is a marker of vascular injury and a source of procoagulant activity. Another form of TF, called alternatively spliced has been recently identified in human and murine. It is soluble, circulates in plasma and initiates coagulation and thrombus propagation. Evidence indicates that elevated levels of blood-borne or circulating TF has been associated with metabolic syndrome, type 2 diabetes and cardiovascular risk factors and is a candidate biomarker for future cardiovascular events. Therapeutic strategies have been developed to specifically interfere with TF activity in the treatment of cardiovascular disease.
academia.edu